Heart team approach in treatment of mitral regurgitation: patient selection and outcome.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
07 2020
Historique:
received: 29 02 2020
revised: 20 04 2020
accepted: 20 05 2020
entrez: 22 7 2020
pubmed: 22 7 2020
medline: 22 12 2020
Statut: ppublish

Résumé

A multidisciplinary heart valve team is recommended for the evaluation of treatment in patients with valvular heart disease, but evidence supporting this concept is lacking. In patients with severe mitral regurgitation, we thought to analyse the patient selection process by the heart team for different treatment options and the outcome after treatment. In this single-centre cohort study, all patients treated for mitral regurgitation between July 2013 and September 2018 were included. Primary end points during follow-up were all-cause mortality and a combined end point, consisting of all-cause mortality, cardiovascular rehospitalisation and mitral valve reintervention. 179 patients (44.8%) were treated using Mitraclip, 185 (46.2%) by surgical repair and 36 (9.0%) by surgical replacement. The mortality risk according to EuroScore II differed significantly between treatment groups (6.6%±5.6%, 1.7%±1.5% and 3.6%±2.7% for Mitraclip, surgical repair and replacement, respectively, p<0.001). In-hospital mortality for the 3 groups were 3.4%, 1.6% and 8.3%, respectively (p=0.091). Overall, surgical repair patients had higher 4-year survival (HR 0.40 (95% CI 0.26 to 0.63), p<0.001) and fewer combined end points (HR 0.51 (95% CI 0.32 to 0.80), p<0.001) compared with surgical replacement and Mitraclip patients. However, patients undergoing Mitraclip for isolated, primary mitral regurgitation achieved very good long-term survival. The multidisciplinary heart team assigned only low-risk patients with favourable anatomy to surgical repair, while high-risk patients underwent Mitraclip or surgical replacement. This strategy was associated with lower than expected in-hospital mortality for Mitraclip patients and high 4-year survival rates for patients undergoing surgical or percutaneous repair of isolated primary mitral regurgitation.

Identifiants

pubmed: 32690553
pii: openhrt-2020-001280
doi: 10.1136/openhrt-2020-001280
pmc: PMC7371220
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

N Engl J Med. 2016 Jan 28;374(4):344-53
pubmed: 26550689
Circulation. 2013 Apr 9;127(14):1485-92
pubmed: 23459614
Neth Heart J. 2019 Apr;27(4):176-184
pubmed: 30742250
J Am Soc Echocardiogr. 2012 Jul;25(7):758-65
pubmed: 22537396
J Am Coll Cardiol. 2017 Aug 29;70(9):1121-1131
pubmed: 28838360
J Thorac Cardiovasc Surg. 2012 Aug;144(2):308-12
pubmed: 22698565
Eur Heart J. 2011 Mar;32(5):618-26
pubmed: 20846993
N Engl J Med. 2019 May 16;380(20):1979
pubmed: 31091392
Am J Cardiol. 2020 Apr 1;125(7):1083-1087
pubmed: 31982103
J Am Coll Cardiol. 2015 Dec 29;66(25):2844-2854
pubmed: 26718672
J Am Coll Cardiol. 2013 Mar 5;61(9):903-7
pubmed: 23449424
J Am Coll Cardiol. 2019 May 28;73(20):2609-2635
pubmed: 31010719
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732
Open Heart. 2014 Apr 08;1(1):e000056
pubmed: 25332799
Ann Thorac Surg. 2010 Dec;90(6):1904-11; discussion 1912
pubmed: 21095334
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Thorac Cardiovasc Surg. 2019 Jul;158(1):86-94.e1
pubmed: 30797588
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
J Am Coll Cardiol. 2019 Mar 26;73(11):1250-1260
pubmed: 30898200
J Am Heart Assoc. 2019 Sep 3;8(17):e013332
pubmed: 31441371
N Engl J Med. 2011 Apr 14;364(15):1395-406
pubmed: 21463154
Ann Thorac Surg. 2019 Dec 20;:
pubmed: 31866480
Int J Cardiol. 2019 Feb 15;277:35-41
pubmed: 30153994
JACC Cardiovasc Interv. 2014 Aug;7(8):875-81
pubmed: 25147032
J Am Coll Cardiol. 2015 Jul 21;66(3):308-321
pubmed: 26184623
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442

Auteurs

Mischa Külling (M)

Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Roberto Corti (R)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Georg Noll (G)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Silke Küest (S)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

David Hürlimann (D)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Christophe Wyss (C)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Ivano Reho (I)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Felix C Tanner (FC)

Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.

Jeremy Külling (J)

Swiss Federal Institute of Technology, Zurich, Switzerland.

Nicolai Meinshausen (N)

Swiss Federal Institute of Technology, Zurich, Switzerland.

Oliver Gaemperli (O)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Peter Wenaweser (P)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Sacha P Salzberg (SP)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Thierry Aymard (T)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Jürg Grünenfelder (J)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland.

Patric Biaggi (P)

Heart Clinic Zurich, Hirslanden Hospital Hirslanden, Zurich, Switzerland patric.biaggi@hirslanden.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH